CL2014003569A1 - Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. - Google Patents
Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter.Info
- Publication number
- CL2014003569A1 CL2014003569A1 CL2014003569A CL2014003569A CL2014003569A1 CL 2014003569 A1 CL2014003569 A1 CL 2014003569A1 CL 2014003569 A CL2014003569 A CL 2014003569A CL 2014003569 A CL2014003569 A CL 2014003569A CL 2014003569 A1 CL2014003569 A1 CL 2014003569A1
- Authority
- CL
- Chile
- Prior art keywords
- fge
- iduronate
- sulfatase
- producing
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
- C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261666712P | 2012-06-29 | 2012-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003569A1 true CL2014003569A1 (es) | 2015-04-17 |
Family
ID=49778402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003569A CL2014003569A1 (es) | 2012-06-29 | 2014-12-29 | Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20140004097A1 (es) |
| EP (1) | EP2867367A4 (es) |
| JP (1) | JP2015523074A (es) |
| KR (1) | KR20150037908A (es) |
| CN (1) | CN104583414A (es) |
| AU (1) | AU2013282417A1 (es) |
| BR (1) | BR112014032544A2 (es) |
| CA (1) | CA2877492A1 (es) |
| CL (1) | CL2014003569A1 (es) |
| CO (1) | CO7240395A2 (es) |
| CR (1) | CR20140587A (es) |
| DO (1) | DOP2014000297A (es) |
| EA (1) | EA201492185A1 (es) |
| HK (2) | HK1209458A1 (es) |
| IL (1) | IL236324A0 (es) |
| IN (1) | IN2014DN11272A (es) |
| MX (1) | MX2015000188A (es) |
| PE (1) | PE20150603A1 (es) |
| PH (1) | PH12014502870A1 (es) |
| SG (1) | SG11201408755TA (es) |
| WO (1) | WO2014005036A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| EP2880156B1 (en) * | 2012-07-31 | 2017-08-23 | biOasis Technologies Inc | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| CN105263958B (zh) | 2013-03-13 | 2019-09-27 | 比奥阿赛斯技术有限公司 | p97片段及其应用 |
| DK3107562T3 (da) * | 2014-02-19 | 2019-12-16 | Bioasis Technologies Inc | P97-ids-fusionsproteiner |
| JP6785777B2 (ja) * | 2015-02-05 | 2020-11-18 | アール．ピー． シェーラー テクノロジーズ エルエルシー | 活性化ホルミルグリシン生成酵素ならびにその生成方法及び使用方法 |
| SG11201802933YA (en) * | 2015-10-07 | 2018-05-30 | Joel Huizenga | Resetting biological pathways for defending against and repairing deterioration from human aging |
| JP7102391B2 (ja) * | 2016-07-25 | 2022-07-19 | レプリゲン・コーポレイション | 交互タンジェンシャルフローによる高速収穫 |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2221361A3 (en) | 1996-08-30 | 2011-02-09 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
| EP1171615B1 (en) * | 1999-04-26 | 2006-12-13 | Genentech, Inc. | Cell culture process for glycoproteins |
| US6890736B1 (en) * | 2002-09-20 | 2005-05-10 | Immunex Corporation | Methods for producing proteins in cultured cells |
| AU2004210936C1 (en) * | 2003-02-11 | 2010-12-02 | Takeda Pharmaceutical Company Limited | Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE) |
| US20050019914A1 (en) * | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
| WO2005113765A2 (en) * | 2004-05-06 | 2005-12-01 | Biomarin Pharmaceutical Inc. | Methods of activation of sulfatases and methods and compositions of using the same |
| EP1885753B1 (en) * | 2005-06-03 | 2011-07-27 | Ares Trading S.A. | Production of recombinant Il-18 binding protein |
| ES2434494T3 (es) * | 2005-12-08 | 2013-12-16 | Amgen, Inc. | Células huésped mejoradas y métodos de cultivo |
| CN105274072A (zh) | 2008-01-18 | 2016-01-27 | 生物马林药物股份有限公司 | 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用 |
| WO2011044542A1 (en) * | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| WO2011109600A1 (en) * | 2010-03-05 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| RU2660348C2 (ru) | 2010-06-25 | 2018-07-05 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки в цнс идуронат-2-сульфатазы |
| KR101158673B1 (ko) * | 2011-06-24 | 2012-07-03 | 주식회사 지씨바이오 | 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법 |
| US9150841B2 (en) * | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
-
2013
- 2013-03-14 US US13/829,811 patent/US20140004097A1/en not_active Abandoned
- 2013-06-28 PE PE2014002540A patent/PE20150603A1/es not_active Application Discontinuation
- 2013-06-28 SG SG11201408755TA patent/SG11201408755TA/en unknown
- 2013-06-28 CN CN201380042616.9A patent/CN104583414A/zh active Pending
- 2013-06-28 JP JP2015520577A patent/JP2015523074A/ja active Pending
- 2013-06-28 EP EP13810106.8A patent/EP2867367A4/en not_active Withdrawn
- 2013-06-28 MX MX2015000188A patent/MX2015000188A/es unknown
- 2013-06-28 BR BR112014032544A patent/BR112014032544A2/pt not_active IP Right Cessation
- 2013-06-28 IN IN11272DEN2014 patent/IN2014DN11272A/en unknown
- 2013-06-28 CA CA2877492A patent/CA2877492A1/en not_active Abandoned
- 2013-06-28 WO PCT/US2013/048601 patent/WO2014005036A1/en active Application Filing
- 2013-06-28 EA EA201492185A patent/EA201492185A1/ru unknown
- 2013-06-28 KR KR1020157002278A patent/KR20150037908A/ko not_active Application Discontinuation
- 2013-06-28 AU AU2013282417A patent/AU2013282417A1/en not_active Abandoned
-
2014
- 2014-12-17 CR CR20140587A patent/CR20140587A/es unknown
- 2014-12-17 IL IL236324A patent/IL236324A0/en unknown
- 2014-12-22 PH PH12014502870A patent/PH12014502870A1/en unknown
- 2014-12-22 DO DO2014000297A patent/DOP2014000297A/es unknown
- 2014-12-26 CO CO14284195A patent/CO7240395A2/es unknown
- 2014-12-29 CL CL2014003569A patent/CL2014003569A1/es unknown
-
2015
- 2015-10-14 HK HK15110043.9A patent/HK1209458A1/xx unknown
- 2015-10-26 HK HK15110518.5A patent/HK1209790A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1209458A1 (en) | 2016-04-01 |
| KR20150037908A (ko) | 2015-04-08 |
| EP2867367A4 (en) | 2016-02-24 |
| WO2014005036A1 (en) | 2014-01-03 |
| PH12014502870A1 (en) | 2015-02-23 |
| CO7240395A2 (es) | 2015-04-17 |
| EA201492185A1 (ru) | 2015-10-30 |
| SG11201408755TA (en) | 2015-02-27 |
| IN2014DN11272A (es) | 2015-10-09 |
| JP2015523074A (ja) | 2015-08-13 |
| BR112014032544A2 (pt) | 2017-08-01 |
| MX2015000188A (es) | 2015-04-08 |
| CR20140587A (es) | 2015-04-06 |
| HK1209790A1 (en) | 2016-04-08 |
| EP2867367A1 (en) | 2015-05-06 |
| AU2013282417A1 (en) | 2015-01-29 |
| DOP2014000297A (es) | 2015-04-15 |
| IL236324A0 (en) | 2015-02-26 |
| US20140004097A1 (en) | 2014-01-02 |
| PE20150603A1 (es) | 2015-05-27 |
| CN104583414A (zh) | 2015-04-29 |
| CA2877492A1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014003569A1 (es) | Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. | |
| MY187874A (en) | Antibody formulations | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| CL2011002222A1 (es) | Metodo para preparar una proteina biologica condicionalmente activa; metodo para preparar un modificador condicionalmente activo de respuesta biologica. | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
| BR112013002249A2 (pt) | meio de cultura de células, métod para obter e/ou cultivar um organóide de fígado, população de células-tronco de fígado adultas ou um organóide de fígado, organóide de fígado, e uso de um organóide de fígado | |
| CO6440530A2 (es) | Formulaciones de caldo de fermentación | |
| WO2012045082A3 (en) | Engineered nucleic acids and methods of use thereof | |
| PE20150957A1 (es) | Celulas para producir iduronato-2-sulfatasa recombinante | |
| BR112012015721A2 (pt) | modificação covalente de proteínas dirigida por ligante | |
| WO2012142591A3 (en) | Compositions, methods and uses for multiplex protein sequence activity relationship mapping | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| BR112013004776A2 (pt) | moduladores de proteína notum e métodos de uso | |
| MY170720A (en) | Antibody formulations | |
| BR112013030321A2 (pt) | composição de vacina, método para preparar a composição de vacina, uso da composição de vacina, método para imunizar um porco, cepa de vacina contra csfv e uso de uma célula no cultivo de uma cepa de vacina contra csfv. | |
| BR112012030678A2 (pt) | células-tronco da geleia de wharton nativa e sua purificação | |
| AR089752A1 (es) | Anticuerpos anti-lrp5 y metodos de uso | |
| NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
| CL2013000237A1 (es) | Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo. | |
| AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| GB2496356A (en) | Pharmaceutical composition and method of inhibiting of production or amplifying elimination of P24 protein | |
| TW201613631A (en) | Ghrelin secretion promoter |